Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.

Literature DB >> 2496654

In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.

F A Sarubbi¹, A Verghese, C Caggiano, S Holtsclaw-Berk, S L Berk.

Abstract

Cefpodoxime proxetil (U-76,252; CS-807) is a new esterified oral cephem antibiotic with a broad antibacterial spectrum. Since data regarding the activity of cefpodoxime against Branhamella catarrhalis are limited, we tested its activity against 200 B. catarrhalis isolates. The drug was highly active against beta-lactamase-negative and -positive isolates; 99% of all strains tested showed a cefpodoxime proxetil MIC of less than or equal to 2.0 micrograms/ml.

Entities: Chemical Species

Mesh：

Substances：

Year: 1989 PMID： 2496654 PMCID： PMC171432 DOI： 10.1128/AAC.33.1.113

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.

Authors: S Alvarez; M Jones; S Holtsclaw-Berk; J Guarderas; S L Berk
Journal: Antimicrob Agents Chemother Date: 1985-04 Impact factor: 5.191

2. Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.

Authors: A L Barry; R N Jones
Journal: J Clin Microbiol Date: 1988-04 Impact factor: 5.948

3. In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods.

Authors: G V Doern; T A Tubert
Journal: Antimicrob Agents Chemother Date: 1988-02 Impact factor: 5.191

4. beta-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid.

Authors: T Farmer; C Reading
Journal: Antimicrob Agents Chemother Date: 1982-03 Impact factor: 5.191

5. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.

Authors: N X Chin; H C Neu
Journal: Antimicrob Agents Chemother Date: 1988-05 Impact factor: 5.191

6. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).

Authors: R N Jones; A L Barry
Journal: Antimicrob Agents Chemother Date: 1988-04 Impact factor: 5.191

7. In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b.

Authors: R Yogev; C Melick; W J Kabat
Journal: Antimicrob Agents Chemother Date: 1981-06 Impact factor: 5.191

8. In vitro susceptibilities of isolates from patients with Branhamella catarrhalis pneumonia compared with those of colonizing strains.

Authors: K G Sweeney; A Verghese; C A Needham
Journal: Antimicrob Agents Chemother Date: 1985-04 Impact factor: 5.191

Review 6. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors: J E Frampton; R N Brogden; H D Langtry; M M Buckley
Journal: Drugs Date: 1992-11 Impact factor: 9.546

6 in total

In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.

1. In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.

2. Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.

3. In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods.

4. beta-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid.

5. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.

6. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).

7. In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b.

8. In vitro susceptibilities of isolates from patients with Branhamella catarrhalis pneumonia compared with those of colonizing strains.

9. Branhamella (Neisseria) catarrhalis: criteria for laboratory identification.

Review 10. Branhamella catarrhalis respiratory infections.

1. Microbiological evaluation of cefpodoxime proxetil.

2. Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.

3. Cefpodoxime proxetil concentrations in head and neck tissues.

4. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.

5. In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer.

Review 6. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.